Informace o publikaci

Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study

Autoři	SCHAFER Sebastian SEILER Isabell KASTNER Lena MEENTS Johannes SLÁVIK Marek BURKOŇ Petr LOI Mauro BONOMO Pierluigi CAMILLA Von Wachter BALERMPAS Panagiotis SCHUNN Anna Sabrina DRABKE Sophia HOLY Richard KLISCHIES Kenneth WITTENSTEIN Olaf WILLNER Jochen BAEHR Andrea BANK Priska PARTL Richard MADER Thomas FRERKER Bernd LOHAUS Fabian EHRET Felix TROMMER Maike GKIKA Eleni RUHLE Alexander GUCKENBERGER Matthias MOUSTAKIS Christos BRUNNER Thomas BLANCK Oliver HEGGEMANN Judit Boda NICOLAY Nils H NAGLER Franziska
Rok publikování	2026
Druh	Recenzovaný odborný článek
Časopis / Zdroj	CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://linkinghub.elsevier.com/retrieve/pii/S2405630826000376
Doi	https://doi.org/10.1016/j.ctro.2026.101142
Klíčová slova	Bone metastases; Breast cancer; Stereotactic radiotherapy; Stereotactic body radiotherapy SBRT; Metastasis-directed therapy (MDT); Spine metastases; Dose concept
Popis	Background and purpose: The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort. Material and methods: Data of breast cancer patients treated with SBRT for BoM between 2010 and 2024 at 17 European cancer centers were retrospectively collected. Treatment and dose concepts were analyzed regarding their impact on freedom from local recurrence (FFLR), overall survival (OS), progression-free survival (PFS), and safety profile. Results: With a median follow-up of 29.6 months (interquartile range: 15.0-48.0), 109 patients with 147 BoM were analyzed. SBRT was performed with a prescribed dose of median 35 Gy in median 5 fractions. 1-/3-year FFLR for mean biologically effective dose (BED10) >= 50 Gy in the gross tumor volume (GTV(mean)) was 98.1% (95%-CI: 92.7%-99.5%) and 93.9% (95%-CI: 85.5%-97.5%), respectively. For GTV(mean) BED10 >= 50 Gy, 1-/3-year PFS was 62.1% (95%-CI: 43.6%-76.0%)/26.7% (95%-CI: 11.0%-45.4%) for non-spine BoM and 66.2% (95%-CI: 50.8%-77.8%)/35.8% (95%-CI: 21.3%-50.4%) for spine BoM. In multivariable analysis, systemic therapy (HR [hazard ratio] 0.22; p < 0.001) was associated with improved OS, while higher GTV(mean )BED10 (HR 0.96; p < 0.001) was associated with improved PFS and spine localization with worse PFS (HR 1.81; p = 0.02). Adverse events were rare, with fracture rates of 2.7%. Conclusion: In this multicenter retrospective cohort analysis, SBRT of BoM from breast cancer was a well-tolerated, effective treatment. Prospective studies are needed to investigate these findings further and determine the role of standardized SBRT concepts in the multidisciplinary management of oligometastatic breast cancer.